New immune therapy trial aims to target tough leukemia
NCT ID NCT03233854
Summary
This early-stage study is testing the safety and side effects of a new type of immune cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or hasn't responded to other treatments. The therapy involves genetically modifying a patient's own immune cells (CAR T-cells) to attack cancer, and may be given with an experimental drug designed to boost the immune system's fight. The main goal is to find the safest dose and see if the treatment can be successfully made for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University, School of Medicine
Palo Alto, California, 94304, United States
Conditions
Explore the condition pages connected to this study.